U.S. pharma large copyright scrapped two experimental weight loss products last 12 months—a once-day by day pill, lotiglipron, because of elevated liver enzymes in addition to a twice-day-to-day tablet, danuglipron, because of potent side effects—but CEO Albert Bourla has reported the company is decided to “Participate in and acquire” withi